Xenon Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenon Pharmaceuticals Inc. on January 3, 2017, reporting events that occurred on January 2, 2017. The filing addresses corporate governance changes regarding the composition of the Board of Directors' standing committees.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on administrative and governance updates rather than financial performance.
Material Changes
Effective January 2, 2017, the Board approved changes to committee memberships based on the recommendation of the Nominating and Corporate Governance Committee:
- Compensation Committee: Dr. Richard Scheller was appointed, replacing Mr. Michael Tarnow.
- Nominating and Corporate Governance Committee: Ms. Dawn Svoronos was appointed, replacing Dr. Mohammad Azab.
The updated committee memberships are as follows:
| Committee | Members |
|---|---|
| Audit Committee | Frank Holler (Chair), Steven Gannon, Michael Tarnow |
| Compensation Committee | Dr. Mohammad Azab (Chair), Dr. Gary Patou, Dr. Richard Scheller |
| Nominating and Corporate Governance Committee | Dr. Gary Patou (Chair), Michael Tarnow, Dawn Svoronos |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the effective date of the committee changes (January 2, 2017).
- Confirm the new composition of the Audit, Compensation, and Nominating and Corporate Governance committees.
- Note that this filing contains no financial data or operational updates.